IONIS PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 19, 2025
IONS$28.19-9.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock · Additional · Accumulated Other · Accumulated · Total Ionis Stockholders’ | ||||||
|---|---|---|---|---|---|---|
| Description | Shares | Amount | Paid in Capital | Comprehensive Loss | Deficit | Equity |
| Balance at December 31, 2021 | 141,210 | $141 | $1,964,167 | $(32,668) | $(1,159,903) | $771,737 |
| Net loss | — | — | — | — | (269,722) | (269,722) |
| Change in unrealized losses, net of tax | — | — | — | (24,395) | — | (24,395) |
| Foreign currency translation | — | — | — | (417) | — | (417) |
| Issuance of common stock in connection with employee stock plans, net | 1,194 | 1 | 6,372 | — | — | 6,373 |
| Stock-based compensation expense | — | — | 100,264 | — | — | 100,264 |
| Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options | (346) | — | (10,953) | — | — | (10,953) |
| Balance at December 31, 2022 | 142,058 | $142 | $2,059,850 | $(57,480) | $(1,429,625) | $572,887 |
| Net loss | — | — | — | — | (366,286) | (366,286) |
| Change in unrealized gains, net of tax | — | — | — | 24,484 | — | 24,484 |
| Foreign currency translation | — | — | — | 351 | — | 351 |
| Issuance of common stock in connection with employee stock plans, net | 2,283 | 2 | 49,439 | — | — | 49,441 |
| Stock-based compensation expense | — | — | 105,809 | — | — | 105,809 |
| Balance at December 31, 2023 | 144,341 | $144 | $2,215,098 | $(32,645) | $(1,795,911) | $386,686 |
| Net loss | — | — | — | — | (453,897) | (453,897) |
| Change in unrealized gains, net of tax | — | — | — | 2,107 | — | 2,107 |
| Foreign currency translation | — | — | — | (273) | — | (273) |
| Issuance of common stock in connection with employee stock plans, net | 2,068 | 2 | 33,607 | — | — | 33,609 |
| Issuance of public common stock, net | 11,500 | 12 | 489,108 | — | — | 489,120 |
| Stock-based compensation expense | — | — | 130,999 | — | — | 130,999 |
| Balance at December 31, 2024 | 157,909 | $158 | $2,868,812 | $(30,811) | $(2,249,808) | $588,351 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.